Cargando…

Proprotein Convertase Subtilisin/Kexin Type 6: A Risk Factor for Survival in Pulmonary Fibrosis?

Detalles Bibliográficos
Autor principal:	Yang, Ivana V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2023
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10263128/ https://www.ncbi.nlm.nih.gov/pubmed/36812412 http://dx.doi.org/10.1164/rccm.202302-0266ED

Ejemplares similares

Proprotein Convertase Subtilisin/Kexin 6 in Cardiovascular Biology and Disease
por: Wu, Qingyu, et al.
Publicado: (2022)

Proprotein Convertase Subtilisin/Kexin Type 9 and Inflammation: An Updated Review
por: Wu, Na-Qiong, et al.
Publicado: (2022)

Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9
por: Chen, I-Chih, et al.
Publicado: (2017)

Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies
por: Ferri, Nicola, et al.
Publicado: (2020)

Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver
por: Shafiq, Muhammad, et al.
Publicado: (2020)

Identification of Novel Proteins Interacting with Proprotein Convertase Subtilisin/Kexin 9
por: Melendez, Quantil M., et al.
Publicado: (2020)

Therapeutic potential of the Proprotein Convertase Subtilisin/Kexin family in vascular disease
por: Suur, Bianca E., et al.
Publicado: (2022)

Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival From Sepsis
por: Lawler, Patrick R., et al.
Publicado: (2023)

Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9
por: Jang, Hyun-Duk, et al.
Publicado: (2020)

Proprotein Convertase Subtilisin/Kexin 9 as a Modifier of Lipid Metabolism in Atherosclerosis
por: Poznyak, Anastasia V., et al.
Publicado: (2023)

Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) on Lipid Metabolism and Insulin Resistance in Human
por: Muraki, Isao
Publicado: (2021)

Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR
por: Wang, Yan, et al.
Publicado: (2012)

Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
por: Schulz, Rainer, et al.
Publicado: (2015)

Hypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9
por: Gu, Hong-mei, et al.
Publicado: (2015)

Variations of the proprotein convertase subtilisin/kexin type 9 gene in coronary artery disease
por: Chiang, Shih-Min, et al.
Publicado: (2019)

Corrigendum to: Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies
Publicado: (2021)

Lipid Parameters and Proprotein Convertase Subtilisin/Kexin Type 9 in Healthy Lebanese Adults
por: Gannagé-Yared, Marie-Hélène, et al.
Publicado: (2022)

Novel Lipid-Lowering Agents Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors: Do They Show Mortality Benefits?
por: Mahajan, Rajiv
Publicado: (2018)

Proprotein convertase subtilisin/kexin type 9: A new target molecule for gene therapy
por: Banaszewska, Anna, et al.
Publicado: (2012)

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders
por: O’Connell, Emma M., et al.
Publicado: (2020)

Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves’ Orbitopathy in Orbital Fibroblasts
por: Lee, Ga Eun, et al.
Publicado: (2021)

Coming Back to Physiology: Extra Hepatic Functions of Proprotein Convertase Subtilisin/Kexin Type 9
por: Schlüter, Klaus-Dieter, et al.
Publicado: (2020)

Application of proprotein convertase subtilisin/kexin type 9 inhibitor, evolocumab, in patients with severe hypertriglyceridemia
por: Peng, Yanren, et al.
Publicado: (2022)

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: The Big Step Forward in Lipid Control
por: Rikhi, Rishi, et al.
Publicado: (2023)

The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease
por: Kim, Eun Ji, et al.
Publicado: (2020)

Proprotein Convertase Subtilisin/Kexin Type 9: From the Discovery to the Development of New Therapies for Cardiovascular Diseases
por: Ferri, Nicola
Publicado: (2012)

Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9)
por: Athavale, Dipti, et al.
Publicado: (2018)

Efficacy and safety of proprotein convertase subtilisin/kexin type 9 monoclonal antibody in adults with familial hypercholesterolemia
por: Li, Bin, et al.
Publicado: (2016)

Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer’s Disease
por: Adorni, Maria Pia, et al.
Publicado: (2019)

Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects
por: Duprez, Daniel A, et al.
Publicado: (2020)

Proprotein convertase subtilisin/kexin type 9 inhibition in cardiovascular disease: current status and future perspectives
por: Cho, Kyung Hoon, et al.
Publicado: (2020)

Acute Tubular Injury in a Patient on a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
por: Pickett, June K., et al.
Publicado: (2020)

Diverse Effects of Cilostazol on Proprotein Convertase Subtilisin/Kexin Type 9 between Obesity and Non-Obesity
por: Chen, Po-Wei, et al.
Publicado: (2022)

Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome
por: Metkus, Thomas S., et al.
Publicado: (2022)

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gene Is a Risk Factor of Large-Vessel Atherosclerosis Stroke
por: Abboud, Shérine, et al.
Publicado: (2007)

Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels and Cardiometabolic Risk Factors: A Population-Based Cohort Study
por: Shi, Jie, et al.
Publicado: (2021)

Characterization of a quantitative method to measure free proprotein convertase subtilisin/kexin type 9 in human serum
por: Colbert, Alexander, et al.
Publicado: (2014)

Proprotein Convertase Subtilisin/Kexin Type 3 Promotes Adipose Tissue-Driven Macrophage Chemotaxis and Is Increased in Obesity
por: Kappert, Kai, et al.
Publicado: (2013)

Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia
por: Mazhar, Faizan, et al.
Publicado: (2016)

Proprotein convertase subtilisin/kexin type 9 (PCSK9) Deficiency is Protective Against Venous Thrombosis in Mice
por: Wang, Hui, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_altafobj4sl0ocjvpois3fqj6e